These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 17617284)

  • 1. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
    Ousler GW; Workman DA; Torkildsen GL
    Clin Ther; 2007 Apr; 29(4):611-6. PubMed ID: 17617284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study.
    Torkildsen GL; Ousler GW; Gomes P
    Clin Ther; 2008 Jul; 30(7):1264-71. PubMed ID: 18691985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
    Abelson MB; Gomes P; Crampton HJ; Schiffman RM; Bradford RR; Whitcup SM
    Clin Ther; 2004 Jan; 26(1):35-47. PubMed ID: 14996516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
    Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
    Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Assessment of the clinical efficacy and safety of epinastine plus pseudoephedrine vs loratadine plus pseudoephedrine in perennial allergic rhinitis].
    Hernández Colín D; González Díaz SN; Rodríguez Medina R; Aguilar Angeles D; González Gámez J; Becerril Angeles M; Orea Solano M; Domínguez Henkel R; Segovia Ayala C
    Rev Alerg Mex; 2004; 51(1):23-8. PubMed ID: 15119752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride.
    Ousler GW; Wilcox KA; Gupta G; Abelson MB
    Ann Allergy Asthma Immunol; 2004 Nov; 93(5):460-4. PubMed ID: 15562885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
    Lanier BQ; Gross RD; Marks BB; Cockrum PC; Juniper EF
    Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.
    Villareal AL; Farley W; Pflugfelder SC
    Eye Contact Lens; 2006 Dec; 32(6):272-6. PubMed ID: 17099387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye.
    Lekhanont K; Park CY; Combs JC; Suwan-Apichon O; Rangsin R; Chuck RS
    J Ocul Pharmacol Ther; 2007 Feb; 23(1):83-8. PubMed ID: 17341156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epinastine 0.05% ophthalmic solution in contact lens-wearing subjects with a history of allergic conjunctivitis.
    Nichols KK; Morris S; Gaddie IB; Evans D
    Eye Contact Lens; 2009 Jan; 35(1):26-31. PubMed ID: 19125045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis.
    Tagawa Y; Namba K; Nakazono Y; Iwata D; Ishida S
    Allergol Int; 2017 Apr; 66(2):338-343. PubMed ID: 27720602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical levocabastine compared with oral loratadine for the treatment of seasonal allergic rhinoconjunctivitis. Swedish GP Allergy Team.
    Allergy; 1994 Sep; 49(8):611-5. PubMed ID: 7653738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
    Abelson MB; Lanier RQ
    Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms.
    Torkildsen GL; Gomes P; Welch D; Gopalan G; Srinivasan S
    Clin Exp Allergy; 2009 Jul; 39(7):1052-9. PubMed ID: 19302250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
    Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
    Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.